Frovatriptan May Offer Relief From Migraine Pain

migraine Throbbing pain, nausea, and intense sensitivity to light and sound: people who suffer from migraine headaches are all too familiar with these symptoms. Frovatriptan is a medication approved by the United States Food and Drug Administration (FDA) for acute treatment of migraine attacks with or without aura in adults.

How It Works

Frovatriptan belongs to the triptan class of drugs. Other triptans are currently used to treat migraine headaches as well. However, frovatriptan has a 26 hours half-life which is much longer than the other triptans. This means that frovatriptan stays in the bloodstream longer than the other drugs. However, this does not mean that frovatriptan works better than other triptans, just that it may be taken less often or last longer.

The theory regarding the origins of a migraine headache has been debated for years. One explanation is neurovascular theory, which suggests that headache is a result of activation of the trigeminal nerve, 1 of the cranial nerves. Some experts believe that the headache is related to sudden widening of blood vessels. Frovatriptan may work by constricting the blood vessels in the brain that cause the migraine headache. However, the precise mechanism of action is not established.

Frovatriptan tablets should be taken with fluids as soon as a migraine hits. If the headache comes back after initial relief, after 2 hours, a second dose can be taken. Do not take more than 3 tablets in 24 hours.

From the Labs

4 clinical trials examined the effects of frovatriptan on migraine pain. In all 4 studies, the percentage of people reporting some relief of headache pain within 2 hours of taking the medication was greater in the group receiving 2.5 mg of frovatriptan than in the group given the placebo. In addition, less than half of people taking frovatriptan needed additional medication (such as aspirin) to help stop the pain.

Frovatriptan appears to have a low incidence of side effects. These may include:

  • Lightheadedness
  • Fatigue
  • Tingling or prickling sensation
  • Flushing
  • Dry mouth
  • Hot or cold sensation
  • Chest pain
  • Indigestion
  • Nausea
  • Drowsiness
  • Skeletal pain

People with certain conditions should not take frovatriptan; these include people with:

Serotonin Syndrome

A life-threatening condition called serotonin syndrome can happen when triptans, such as frovatriptan, and medications used to treat depression, called selective serotonin reuptake inhibitors (SSRIs), are used together. If you are taking SSRIs, make sure you let your doctor know.

Signs and symptoms of serotonin syndrome include the following:

  • Restlessness
  • Hallucinations
  • Loss of coordination
  • Fast heart beat
  • Increased body temperature
  • Fast changes in blood pressure
  • Overactive reflexes
  • Diarrhea
  • Coma
  • Nausea
  • Vomiting

RESOURCES:

American Headache Society Committee for Headache Education
http://www.achenet.org
United States Food and Drug Administration
http://www.fda.gov

CANADIAN RESOURCES:

College of Family Physicians Canada
http://www.cfpc.ca

References:

FROVA (frovatriptan succinate) tablet, film coated [Endo Pharmaceuticals]. Daily Med website. Available at:
...(Click grey area to select URL)
Updated October 2013. Accessed June 23, 2016.
Frovatriptan. EBSCO DynaMed website. Available at:
...(Click grey area to select URL)
Updated May 6, 2016. Accessed June 23, 2016.
Frova. Migraine Awareness Group website. Available at:
...(Click grey area to select URL)
Accessed June 23, 2016.
Migraine. National Headache Foundation website. Available at:
...(Click grey area to select URL)
Published October 25, 2007. Accessed June 23, 2016.
Migraine—treatment of acute attack. Available at:
...(Click grey area to select URL)
Updated March 23, 2016. Accessed June 23, 2016.
Serotonin syndrome. EBSCO DynaMed website. Available at:
...(Click grey area to select URL)
Updated April 2, 2015. Accessed June 23, 2016.
Triptans. EBSCO DynaMed website. Available at:
...(Click grey area to select URL)
Updated August 11, 2015. Accessed June 23, 2016.
Last reviewed June 2016 by Michael Woods, MD
Last Updated: 7/16/2014

EBSCO Information Services is fully accredited by URAC. URAC is an independent, nonprofit health care accrediting organization dedicated to promoting health care quality through accreditation, certification and commendation.

This content is reviewed regularly and is updated when new and relevant evidence is made available. This information is neither intended nor implied to be a substitute for professional medical advice. Always seek the advice of your physician or other qualified health provider prior to starting any new treatment or with questions regarding a medical condition.

To send comments or feedback to our Editorial Team regarding the content please email us at healthlibrarysupport@ebsco.com. Our Health Library Support team will respond to your email request within 2 business days.

advertisement